Full-Time

Senior Manager

Regulatory Affairs

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$135k - $175kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Business Strategy
Requirements
  • Bachelor's Degree in a relevant field and at least 5 years of direct Regulatory experience.
  • Strong working knowledge of US FDA Pharmaceutical regulations and guidance.
  • Proven track record of successful submissions within a regulatory environment.
  • Exceptionally strong team player with excellent interpersonal and communication skills.
  • Detail-oriented with strong organizational skills and high-quality standards.
Responsibilities
  • Manage planning, preparation, coordination, and submission of regulatory documents to global National Health Authorities. Such submissions may include Clinical, Preclinical, or CMC content.
  • Correspond and collaborate with RevMed colleagues and departments to achieve alignment.
  • Function as a Regulatory Affairs subject matter expert member of cross-functional teams, including study teams and submission teams.
  • Perform regulatory research to inform business strategy. Assess and communicate risks.
  • Assure that there are no significant interruptions to the business due to regulatory compliance issues.
  • Collaborates across the organization at all levels, across functional groups, and with executive management.
  • Develop regulatory strategies to inform associated budgets, tools and specialized support necessary for efficient operations.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?